HSV gB Specific Neutra™ Antibody Products

Are you facing challenges in neutralizing herpesvirus infectivity or developing antibodies with high specificity for viral entry inhibition? Creative Biolabs’ HSV gB specific Neutra™ antibody products leverage advanced recombinant protein engineering and affinity-matured validation to enable precise targeting of HSV gB, accelerating therapeutic development and enhancing functional analysis of viral entry mechanisms.

Introduction to HSV gB

Herpesvirus glycoprotein B (HSV gB), a highly conserved type III viral fusion protein, is essential for mediating viral entry into host cells. As the most abundant envelope glycoprotein in herpes simplex virus (HSV) types 1 and 2, gB facilitates membrane fusion between the viral envelope and host cell membranes. This process is indispensable for viral infectivity and subsequent intracellular replication, positioning gB as a central therapeutic target for disrupting viral pathogenesis.

Fig.1 Models of HSV-1 entry into host cells.¹

• Structural Insights

HSV gB is composed of four structural domains: an N-terminal cytoplasmic region, a central ectodomain, a transmembrane domain, and a C-terminal tail. The ectodomain undergoes conformational changes to drive membrane fusion, a mechanism elucidated through cryo-EM studies. Trimeric gB complexes interact with host receptors such as paired immunoglobulin-like type 2 receptor alpha (PILRα), triggering fusogenic activity. Notably, antigenic domains in the ectodomain—including neutralizing epitopes in Domain I and V—serve as critical targets for antibody-mediated inhibition of viral entry.

• Signaling Pathways and Pathogenicity

HSV gB activates host cell signaling pathways, including PI3K/Akt and NF-κB, to promote viral internalization and immune evasion. By modulating these pathways, gB enhances viral survival and latency establishment in sensory neurons. Persistent infections mediated by HSV gB contribute to recurrent mucocutaneous lesions, keratitis, and encephalitis, underscoring its role in both acute and chronic pathologies.

• Associated Diseases

HSV infections, driven by gB-mediated entry, are linked to orofacial and genital lesions, neonatal herpes, and severe complications in immunocompromised individuals. Persistent viral latency in neural ganglia often leads to recurrent outbreaks, emphasizing the need for therapeutic strategies targeting gB to prevent viral reactivation and transmission.

Applications of Anti-HSV gB Neutralizing Antibodies

• Therapeutic Development for HSV Infections

Anti-HSV gB antibodies are pivotal in designing biologics to prevent viral entry and reduce lesion severity. Passive immunization studies demonstrate their efficacy in lowering viral loads and preventing neuronal spread, offering promise for treating immunocompromised patients and neonatal herpes.

• Diagnostic Assay Development

High-affinity anti-gB antibodies enable sensitive detection of HSV in clinical samples via ELISA and lateral flow assays. These tools are critical for early diagnosis, seroprevalence studies, and monitoring therapeutic responses in vaccine trials.

• Vaccine Efficacy Evaluation

gB-specific neutralizing antibodies serve as biomarkers to assess vaccine-induced immune responses. Preclinical models show that gB-targeting vaccines elicit robust antibody titers, correlating with protection against primary and recurrent infections.

• Antiviral Mechanism Studies

Anti-gB antibodies are used to map fusion intermediates and identify host factors involved in viral entry. This research informs the development of small-molecule inhibitors targeting gB conformational changes.

Our Anti-HSV gB Neutralizing Antibodies

Creative Biolabs' anti-HSV gB antibodies are engineered to target conformational epitopes critical for membrane fusion. These antibodies demonstrate:

- High Neutralization Potency: Block gB-host receptor interactions and inhibit viral entry across HSV-1 and HSV-2 strains.

- Cross-Reactivity: Recognize conserved regions in gB, enabling broad-spectrum antiviral activity.

- Precision in Functional Assays: Validated in neutralization assays, ELISA, and immunofluorescence to quantify gB expression and fusion activity.

Creative Biolabs offers HSV gB specific Neutra™ antibody products with unmatched specificity and reproducibility to advance your antiviral research.

Contact our scientific team today to discuss custom antibody development, bulk orders, or application support.

REFERENCE

1. Jambunathan, Nithya, et al. "Two sides to every story: herpes simplex type-1 viral glycoproteins gB, gD, gH/gL, gK, and cellular receptors function as key players in membrane fusion." Viruses 13.9 (2021): 1849. Distributed under Open Access license CC BY 4.0. The image was modified by extracting and using only part of the original image. https://doi.org/10.3390/v13091849